News for Mesoblast Limited (MEOBF)

Published at

May 15, 2025 1:01 PM

by gurufocus.com

positive

positive

Mesoblast (MEOBF) Gains Orphan-Drug Exclusivity for Ryoncil | MEOBF Stock News

Mesoblast (MEOBF) has secured a significant regulatory win with the U.S. Food and Drug Administration granting a seven-year orphan-drug exclusivity for its prod

MEOBF

Read more →
Published at

May 15, 2025 5:17 AM

by manilatimes.net

positive

positive

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

**media[626419]**

MSB.AX MESO MEOBF

Read more →
Published at

Apr 30, 2025 4:15 AM

by gurufocus.com

positive

positive

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 | MESO Stock News

Mesoblast (MESO) launched Ryoncil® in the US, the first FDA-approved MSC therapy. Ryoncil® coverage extends to over 104 million US lives, with 37 stat

MSB.AX MESO MEOBF

Read more →
Published at

Apr 30, 2025 4:00 AM

by gurufocus.com

positive

positive

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, toda

MSB.AX MESO MEOBF

Read more →
Published at

Apr 30, 2025 3:05 AM

by manilatimes.net

positive

positive

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

**media[609639]**

MSB.AX MESO MEOBF

Read more →
Published at

Apr 29, 2025 2:05 AM

by manilatimes.net

mixed

mixed

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

**media[608202]**

MSB.AX MESO MEOBF CMWAY CBAUF CBAPJ.AX

Read more →
Published at

Apr 17, 2025 5:00 AM

by gurufocus.com

positive

positive

Mesoblast (MESO) Expands Ryoncil Coverage to 104 Million Insured Lives | MEOBF Stock News

Mesoblast (MESO) has reported a significant expansion in insurance coverage for its mesenchymal stromal cell therapy, Ryoncil. This marks the first treatment in

MEOBF

Read more →
Published at

Apr 11, 2025 2:14 PM

by benzinga.com

mixed

mixed

Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Booz Allen Hamilton (NYSE:BAH), Betterware de Mexico SAPI (NYSE:BWMX)

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Friday. Shares of Booz Allen Hamilton Holding Corporation BAH fell sha...

SLSSF SLS.V SLS.TO NEXA.TO NEXA BAH.MX 0HOT.L MSB.AX MOV MESO MEOBF DYN BAH INNV CMRE

Read more →
Published at

Apr 9, 2025 11:10 PM

by raskmedia.com.au

mixed

mixed

S&P 500 rockets 9% overnight not to be outdone by the Nasdaq up 11%

S&P 500 and Nasdaq rebound 9% and 11% respectively. Australian pharmaceuticals, CSL Limited look to rebound strongly.

MIN.AX MALRY MALRF NEU.AX MSB.AX MESO MEOBF CSLN.MX CSLLY CSL.AX CMXHF

Read more →
Published at

Apr 4, 2025 2:00 AM

by gurufocus.com

positive

positive

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provid

MSB.AX MEOBF

Read more →
Published at

Apr 3, 2025 1:40 AM

by manilatimes.net

positive

positive

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

**media[584512]**

MSB.AX MESO MEOBF

Read more →
Published at

Mar 31, 2025 2:03 AM

by manilatimes.net

positive

positive

First Three Children to Commence Treatment With Ryoncil®

**media[580803]**

MSB.AX MESO MEOBF

Read more →
Published at

Mar 27, 2025 1:34 AM

by manilatimes.net

positive

positive

Ryoncil® is Now Available for Purchase in the United States

**media[577836]**

MSB.AX MESO MEOBF

Read more →
Published at

Mar 14, 2025 2:00 AM

by gurufocus.com

positive

positive

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, toda

MSB.AX MESO MEOBF

Read more →
Published at

Mar 12, 2025 2:00 PM

by gurufocus.com

positive

positive

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, anno

MSB.AX MESO MEOBF

Read more →
Published at

Mar 12, 2025 12:42 PM

by manilatimes.net

positive

positive

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

**media[564251]**

MSB.AX MESO MEOBF

Read more →
Published at

Mar 7, 2025 12:54 AM

by benzinga.com

positive

positive

Mesoblast Added to S&P/ASX 200 INDEX - Mesoblast (NASDAQ:MESO)

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P Dow Jones

MSB.AX MESO MEOBF

Read more →
Published at

Feb 28, 2025 5:38 PM

by seekingalpha.com

positive

positive

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Mesoblast Limited (NASDAQ:MESO) Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive Officer...

MSB.AX MESO MEOBF AND.AX

Read more →
Published at

Feb 26, 2025 11:50 PM

by manilatimes.net

positive

positive

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

**media[551579]**

MSB.AX MESO MEOBF

Read more →
Published at

Feb 26, 2025 3:55 PM

by zacks.com

positive

positive

Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Mesoblast Limited (MESO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

MSB.AX MESO MEOBF

Read more →